Eyegate Pharmaceuticals (NASDAQ: EYEG) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Insider and Institutional Ownership

13.0% of Eyegate Pharmaceuticals shares are held by institutional investors. Comparatively, 36.8% of SCYNEXIS shares are held by institutional investors. 24.6% of Eyegate Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Eyegate Pharmaceuticals and SCYNEXIS, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eyegate Pharmaceuticals 0 0 4 0 3.00
SCYNEXIS 0 1 5 0 2.83

Eyegate Pharmaceuticals presently has a consensus price target of $7.33, indicating a potential upside of 501.09%. SCYNEXIS has a consensus price target of $11.00, indicating a potential upside of 350.82%. Given Eyegate Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Eyegate Pharmaceuticals is more favorable than SCYNEXIS.

Earnings & Valuation

This table compares Eyegate Pharmaceuticals and SCYNEXIS’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Eyegate Pharmaceuticals $767,481.00 27.35 -$13.31 million ($1.30) -0.94
SCYNEXIS $256,999.00 253.70 -$25.04 million N/A N/A

Eyegate Pharmaceuticals has higher revenue and earnings than SCYNEXIS.

Risk and Volatility

Eyegate Pharmaceuticals has a beta of 3.32, meaning that its share price is 232% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

Profitability

This table compares Eyegate Pharmaceuticals and SCYNEXIS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eyegate Pharmaceuticals -1,737.29% -840.69% -105.23%
SCYNEXIS -9,648.47% -64.04% -37.19%

Summary

Eyegate Pharmaceuticals beats SCYNEXIS on 7 of the 12 factors compared between the two stocks.

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

About SCYNEXIS

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.